Curium has agreed to acquire radiopharmaceutical company Lantheus Holdings in a transaction valued at up to $8 billion.
The companies confirmed the agreement on Monday, signaling a major shift in the competitive landscape for nuclear medicine providers.
Under the terms of the deal, Lantheus shareholders will receive $102.
Under the terms of the deal, Lantheus shareholders will receive $102.50 per share in cash.
The acquisition represents a substantial bet on the growth of targeted radionuclide therapies, as Curium seeks to expand its portfolio and market presence through this strategic combination.
The move comes amid a broader trend of consolidation in the healthcare sector, where larger players are increasingly looking to acquire specialized peers to bolster their pipelines and commercial reach.
This deal follows other high-profile transactions in recent months, including Rocket Lab’s $8 billion acquisition aimed at competing in satellite broadband, highlighting the scale of capital deployment in specialized industries.